Advertisement

Breast Cancer Oncology

Black women are more likely to develop lymphedema following breast cancer treatment

Dec 15, 2021

Development of breast cancer-related lymphedema is not equally distributed between races. Black women experienced higher rates of breast cancer-related lymphedema than White women, results of a prospe...

Promising anti-tumour activity of the CDK7-inhibitor samuraciclib (plus fulvestrant) in pre-treated ER-positive/HER2-negative metastatic breast cancer

Dec 15, 2021

Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic breast cancer who progress on an aromatase inhibitor plus CDK4/6 inhibitor is poor. In a first-in-human ...

ctDNA is prognostic and predictive for response to ribociclib/letrozole

Dec 15, 2021

The phase 3 BioItaLEE trial demonstrates that pre-treatment circulating tumor DNA (ctDNA) and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with HR-posit...

Olaparib is well tolerated as an additional adjuvant treatment

Dec 15, 2021

Adjuvant treatment with the PARP inhibitor olaparib showed beneficial effects for patients with BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer. In addition, patient...

Neratinib/trastuzumab is clinically active in patients with heavily pre-treated, metastatic, HER2-mutated breast cancer.

Dec 15, 2021

Both patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast cancer and patients with heavily pre-treated HER2-mutated metastatic triple-negative breast cancer (TN...

Aromatase inhibitors outperform tamoxifen in reducing recurrence in pre-menopausal women

Dec 15, 2021

In pre-menopausal women with early-stage, ER-positive breast cancer, adjuvant ovarian suppression can be combined with tamoxifen or an aromatase inhibitor. A meta-analysis of 4 randomized controlled t...

Taxane with or without anthracycline?

Dec 15, 2021

Taxane with or without anthracycline reduces the recurrence rate of early-stage breast cancer. A meta-analysis based on data of 18,203 participants now demonstrates anthracycline/taxane to reduce the ...

Head-to-head comparison of trastuzumab deruxtecan and trastuzumab emtansine favors the first

Dec 14, 2021

Both adjuvant therapy with trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have shown to improve progression-free survival in patients with HER2-positive, metastatic breast cancer. In...

Breast cancer patients with ER mutations may benefit from early switch to fulvestrant/palbociclib

Dec 14, 2021

Among patients with HR-positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed rising ESR1 mutations before disease progression doubled their median progressio...

Evolution of physical activity and body weight changes in breast cancer survivors five years after diagnosis - VICAN 2 & 5 French national surveys.

Jul 29, 2021

Regular physical activity (PA) and healthy body weight have proven benefits on survival in breast cancer (BC) survivors. We aimed to define predictors of long-term PA and weight gain in a representati...

Examining Chemotherapy–Radiation Sequencing for Uterine Cancer

Jul 24, 2021

“The optimal adjuvant therapy for women with advanced endometrial cancer remains controversial,” says Gretchen Glaser, MD. “It is unclear how to best sequence adjuvant chemotherapy and radiother...

Black Women Underrepresented in Immunotherapy Trials

Jul 23, 2021

“Racial inequity in healthcare delivery and outcomes in the United States is well-documented, and outcomes for breast and gynecologic cancers are no exception,” explains Katherine V. Grette, MD. ...

Oxoplatin-B, a cisplatin-based platinum(IV) complex with photoactive BODIPY for mitochondria specific "chemo-PDT" activity.

Jul 12, 2021

Oxoplatin-B, a platinum(IV) complex [Pt(NH)Cl(L)(OH)] (1) of 4-methylbenzoic acid (HL) functionalized with 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) was prepared, characterized and its antit...

Multifunctional nanoparticles as theranostic agents for therapy and imaging of breast cancer.

Apr 19, 2021

Over the last decade, there has been significant developments in nanotechnology, in particular for combined imaging and therapeutic applications (theranostics). The core or shell of nanoemulsions (NEs...

Characteristics of clinically node negative breast cancer patients needing preoperative MRI.

Apr 19, 2021

International guidelines do not recommend magnetic resonance imaging (MRI) for all breast cancer patients at primary diagnostics. This study aimed to understand which patient or tumor characteristics ...

Phyllodes tumors of the breast: Adjuvant radiation therapy revisited.

Apr 19, 2021

Phyllodes tumors (PT) are rare entity and surgical resection is the cornerstone of treatment. No standard of care exists regarding adjuvant treatment especially radiation therapy (RT).We analyzed all ...

Covid-19: Updated Guidance on Vaccines, Masks, and... Mammograms?

Feb 16, 2021

Public health organizations release new recommendations as pandemic rages on The CDC and other public health entities recently issued a host of new Covid-19 guidance, with recommendations covering to...

Empathy, The Best Medicine? How Doctors can Help Patients Remember More Information and Make Better-Informed Decisions

Jan 29, 2021

The expression “It shouldn’t have to happen to you to matter to you” has been making the rounds on social media platforms lately. In my opinion, it’s a great way to define empathy, our ability...

Eribulin with/without Pembrolizumab for Metastatic Breast Cancer

Sep 17, 2020

In women with metastatic breast cancer, programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors are given as the primary line of monotherapy. However, in patients with hormone...

Pembrolizumab Plus Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

Aug 25, 2020

Neoadjuvant chemotherapy is routinely assigned to women with early-stage breast cancer, but approximately 25% of them experience a recurrence within 5 years. Combining pembrolizumab, a humanized antib...